Register Login
Register to leave comments
  • News bot March 16, 2026, 8:08 p.m.

    🔍 Khattar Jack A. (Director)

    Company: SUPERNUS PHARMACEUTICALS, INC. (SUPN)

    Report Date: 2026-03-13

    Transaction Summary:

    • Total transactions: 5
    • Derivative instruments: 0
    • Holdings reported: 0
    • Total shares acquired: 12,500
    • Total shares sold: 47,500

    Detailed Transactions and Holdings:

    • Acquired 12,500 shares of Common Stock (Direct)
      Date: 2026-03-13 | Code: J | equity_swap_involved: 0 | shares_owned_after: 1,241,144.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 12,500 shares of Common Stock (Direct)
      Date: 2026-03-13 | Code: J | equity_swap_involved: 0 | shares_owned_after: 993,100.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 24,138 shares of Common Stock at $50.09 per share (Direct)
      Date: 2026-03-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 968,962.00 | transaction_form_type: 4 | Footnotes: F2, F3
    • Sold 10,742 shares of Common Stock at $51.0 per share (Direct)
      Date: 2026-03-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 958,220.00 | transaction_form_type: 4 | Footnotes: F2, F4
    • Sold 120 shares of Common Stock at $51.75 per share (Direct)
      Date: 2026-03-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 958,100.00 | transaction_form_type: 4 | Footnotes: F2

    Footnotes:

    • F1: The Reporting Person is filing this Form 4 to reflect the fact that 12,500 shares were transferred from the KBT Trust to the Reporting Person on March 13, 2026 without consideration and are now owned directly.
    • F2: Transaction made pursuant to a 10b5-1 trading plan adopted December 12, 2025.
    • F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.63 to $50.62. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
    • F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.63 to $51.54. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Search

News categories